New Herceptin early breast cancer regimens

Copyright © F. Hoffmann-La Roche Ltd
Copyright © F. Hoffmann-La Roche Ltd

Herceptin (trastuzumab) has had its licence for use in HER2-positive early breast cancer extended.

In addition to use following surgery, chemotherapy and radiotherapy, it is now also recommended in:

  • combination with paclitaxel or docetaxel following adjuvant chemotherapy with doxorubicin and cyclophosphamide, or;
  • combination with docetaxel and carboplatin.

In early breast cancer patients, cardiac monitoring should be performed before treatment initiation, every 3 months during treatment and every 6 months for 2 years from the last dose of Herceptin.

View Herceptin drug record

Further Information: Roche Products Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Early emollient use does not prevent eczema in children

Early emollient use does not prevent eczema in children

Daily application of emollients in infancy is not effective...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Ativan and penicillamine.
Use our constantly...